Aldeyra Therapeutics (ALDX) announced an update on their ongoing clinical study.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Study Overview: Aldeyra Therapeutics recently completed a Phase 2 clinical trial titled A Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects With Moderate Alcohol Associated Hepatitis. The study aimed to evaluate the safety and efficacy of ADX-629, a potential treatment for moderate alcohol-associated hepatitis, a condition with limited therapeutic options.
Intervention/Treatment: The trial tested ADX-629, an experimental drug administered in two dosages: 125 mg and 250 mg, both taken twice daily over a 28-day period. The drug is intended to treat moderate alcohol-associated hepatitis.
Study Design: This interventional study was non-randomized and followed a sequential intervention model. It was open-label, meaning no masking was involved, and its primary purpose was treatment-focused.
Study Timeline: The study began on November 11, 2024, and reached primary completion by December 11, 2025, which is also the date of the last update. These dates are crucial for tracking the study’s progress and data availability.
Market Implications: The completion of this trial could positively impact Aldeyra Therapeutics’ stock performance as it advances ADX-629 closer to market approval. Investors may view this as a promising development, especially given the limited treatment options for alcohol-associated hepatitis. Competitors in the liver disease treatment space may also be monitoring these results closely.
The study is now completed, and further details can be accessed on the ClinicalTrials portal.
To learn more about ALDX’s potential, visit the Aldeyra Therapeutics drug pipeline page.